Bellicum制药(BLCM)

Kevinsnap2015-05-17 10:13

$Bellicum Pharmaceuticals (BLCM)$ "From an acquisition standpoint, Bellicum would fit almost perfectly with Gilead's interests in hematology and oncology. Given that nearly all of Bellicum's product candidates are in preclinical studies or just now entering clinic...查看全文

an小安2015-05-16 10:37

$ Juno Therapeutics (JUNO)$ $Kite Pharma(KITE)$ $Bellicum Pharmaceuticals (BLCM)$ $BLUEBIRD BIO INC(BLUE)$ Novartis/UPenn揭露初始CART-EGFRviii 针对实体瘤脑癌（GBM）的数据: n=3，疗效“modest"。2. 靶向HER2的CART脑癌疗法（HERT-GBM)疗效也是一般：n=16,1 PR (6%)，7 SDs。CART对...查看全文

碧海银沙1112015-05-15 11:11

$Bellicum Pharmaceuticals (BLCM)$ am Bellicum Pharmaceuticals announces DOTTI clinical study results; study patients showed rapid immune reconstitution and reduced infections (BLCM) : Co reported that all 12 study patients showed more rapid immune reconstitution and reduced i...查看全文

Kevinsnap2015-05-14 22:22

$Bellicum Pharmaceuticals (BLCM)$ Study shows T cells engineered with CaspaCIDe improved immune reconstitution Safety switch activation rapidly resolved GvHD symptoms. [看多]
网页链接查看全文

Kevinsnap2015-05-14 13:30

$Bellicum Pharmaceuticals (BLCM)$ 有大神帮忙看看BLCM的数据结果吗？
网页链接查看全文

Kevinsnap2015-05-08 01:19

$Bellicum Pharmaceuticals (BLCM)$ 快发力吧！等死了...查看全文

总结了一下CAR-T相关的股票，欢迎补充指正！

erasee2015-05-05 00:03

$ Juno Therapeutics (JUNO)$ $Kite Pharma(KITE)$ $Bellicum Pharmaceuticals (BLCM)$ $BLUEBIRD BIO INC(BLUE)$ $诺华(NVS)$ $强生(JNJ)$ $ZIOPHARM Oncology(ZIOP)$ $INTREXON CORP(XON)$ $ADRO(ADRO)$查看全文

likeafool822015-05-04 21:54

$Bellicum Pharmaceuticals (BLCM)$ 跌跌不休，捉急啊查看全文

Jackiecz01232015-04-30 05:11

$Bellicum Pharmaceuticals (BLCM)$ HOUSTON, TX – April 29, 2015 – Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced it has entered into a license agr...查看全文

CK小镇2015-04-23 14:14

$Bellicum Pharmaceuticals (BLCM)$狠查看全文

超过5%股东持股披露「修订」

$Bellicum制药(BLCM)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001104659-23-120984  Act: 34  Size: 219 KB 网页链接

持股变动声明

$Bellicum制药(BLCM)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-056578  Size: 22 KB 网页链接

当期报告

$Bellicum制药(BLCM)$ 8-K Current report, items 1.01 and 9.01 Accession Number: 0001628280-23-039830  Act: 34  Size: 808 KB 网页链接

季度财报

$Bellicum制药(BLCM)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001628280-23-038953  Act: 34  Size: 4 MB 网页链接

当期报告

$Bellicum制药(BLCM)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001628280-23-033257  Act: 34  Size: 199 KB 网页链接

当期报告

$Bellicum制药(BLCM)$ 8-K Current report, item 7.01 Accession Number: 0001628280-23-030016  Act: 34  Size: 186 KB 网页链接

季度财报

$Bellicum制药(BLCM)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001628280-23-028893  Act: 34  Size: 4 MB 网页链接

其他

$Bellicum制药(BLCM)$ 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities Accession Number: 0001354457-23-000485  Act: 34  Size: 3 KB 网页链接

当期报告

$Bellicum制药(BLCM)$ 8-K Current report, item 5.02 Accession Number: 0001628280-23-020619  Act: 34  Size: 197 KB 网页链接

当期报告

$Bellicum制药(BLCM)$ 8-K Current report, item 3.01 Accession Number: 0001628280-23-020109  Act: 34  Size: 198 KB 网页链接